在肺腺癌巨细胞中,ANKRD22通过糖溶性通路促进M2两极分化
Jiangbo Cao1, Hongwei Zhang2, Xiaoli Wei3
1Department of Respiratory and Critical Care Medicine, Jingmen People's Hospital, Jingmen, China.
Chemical biology & drug design
|January 17, 2024
概括
这项研究表明,ANKRD22通过糖解增强M2巨细胞极化,促进肺腺癌 (LUAD) 的进展. 针对ANKRD22为LUAD患者提供了潜在的新治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 肺腺癌 (LUAD) 的预后不好,ANKRD22在其进展中的作用尚不清楚.
- 了解驱动LUAD的分子机制对于开发有效疗法至关重要.
研究的目的:
- 研究ANKRD22影响LUAD进展的机制.
- 探索ANKRD22,M2巨细胞极化和LUAD中的糖解之间的关系.
主要方法:
- 生物信息学分析以评估ANKRD22表达和途径丰富.
- 定量逆转录PCR (qRT-PCR),西斑,免疫光学和流动细胞测量来分析基因和蛋白质表达.
- 代谢测试 (海马XF96) 和线粒体潜能评估,以评估细胞代谢和糖解.
主要成果:
- ANKRD22在LUAD中高度表达,并且与M2巨细胞标记物和与糖解相关的基因具有积极的相关性.
- 抑制ANKRD22可降低M2极化,IL-10,CCL17表达,以及关键的糖溶性代谢物和细胞外酸化率 (ECAR).
- ANKRD22通过糖解促进了LUAD M2的两极分化,正如使用糖解抑制剂 (2-DG) 的救援实验所证明的那样.
结论:
- ANKRD22通过糖解路径增强M2巨细胞极化,促进LUAD的进展.
- 准ANKRD22以抑制M2极化是LUAD的一个潜在的治疗策略.
更多相关视频
07:46Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation
Published on: April 3, 2017
25.3K
10:43Polarization of M1 and M2 Human Monocyte-Derived Cells and Analysis with Flow Cytometry upon Mycobacterium tuberculosis Infection
Published on: September 18, 2020
29.1K
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Adaptive Mechanisms in Cancer Cells
5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
Electron Transport Chain: Complex I and II
13.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
13.4K
